Carolyn S Calfee1, Kevin Delucchi2, Polly E Parsons3, B Taylor Thompson4, Lorraine B Ware5, Michael A Matthay6. 1. Departments of Medicine and Anesthesia, Division of Pulmonary and Critical Care Medicine, University of California San Francisco, San Francisco, CA, USA. Electronic address: carolyn.calfee@ucsf.edu. 2. Department of Psychiatry, University of California San Francisco, San Francisco, CA, USA. 3. Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of Vermont, Burlington, VT, USA. 4. Department of Medicine, Pulmonary and Critical Care Medicine Unit, Massachusetts General Hospital, Boston, MA, USA; Biostatistics Unit, Massachusetts General Hospital, Boston, MA, USA. 5. Department of Medicine, Division of Allergy, Pulmonary and Critical Care, Vanderbilt, University, Nashville, TN, USA. 6. Departments of Medicine and Anesthesia, Division of Pulmonary and Critical Care Medicine, University of California San Francisco, San Francisco, CA, USA; Cardiovascular Research Institute, San Francisco, CA, USA.
Abstract
BACKGROUND:Subphenotypes have been identified within heterogeneous diseases such as asthma and breast cancer, with important therapeutic implications. We assessed whether subphenotypes exist within acute respiratory distress syndrome (ARDS), another heterogeneous disorder. METHODS: We used data from two ARDS randomised controlled trials (ARMA trial and ALVEOLI trial), sponsored by the National Heart, Lung, and Blood Institute. We applied latent class modelling to identify subphenotypes using clinical and biological data. We modelled data from both studies independently. We then tested the association of subphenotypes with clinical outcomes in both cohorts and with the response to positive end-expiratory pressure (PEEP) in the ALVEOLI cohort. FINDINGS: We analysed data for 1022 patients: 473 in the ARMA cohort and 549 in the ALVEOLI cohort. Independent latent class models indicated that a two-class (ie, two subphenotype) model was the best fit for both cohorts. In both cohorts, we identified a hyperinflammatory subphenotype (phenotype 2) that was characterised by higher plasma concentrations of inflammatory biomarkers, a higher prevalence of vasopressor use, lower serum bicarbonate concentrations, and a higher prevalence of sepsis than phenotype 1. Participants in phenotype 2 had higher mortality and fewer ventilator-free days and organ failure-free days in both cohorts than did those in phenotype 1 (p<0·007 for all). In the ALVEOLI cohort, the effects of ventilation strategy (high PEEP vs low PEEP) on mortality, ventilator-free days and organ failure-free days differed by phenotype (p=0·049 for mortality, p=0·018 for ventilator-free days, p=0·003 for organ-failure-free days). INTERPRETATION: We have identified two subphenotypes within ARDS, one of which is categorised by more severe inflammation, shock, and metabolic acidosis and by worse clinical outcomes. Response to treatment in a randomised trial of PEEP strategies differed on the basis of subphenotype. Identification of ARDS subphenotypes might be useful in selecting patients for future clinical trials. FUNDING: National Institutes of Health.
RCT Entities:
BACKGROUND: Subphenotypes have been identified within heterogeneous diseases such as asthma and breast cancer, with important therapeutic implications. We assessed whether subphenotypes exist within acute respiratory distress syndrome (ARDS), another heterogeneous disorder. METHODS: We used data from two ARDS randomised controlled trials (ARMA trial and ALVEOLI trial), sponsored by the National Heart, Lung, and Blood Institute. We applied latent class modelling to identify subphenotypes using clinical and biological data. We modelled data from both studies independently. We then tested the association of subphenotypes with clinical outcomes in both cohorts and with the response to positive end-expiratory pressure (PEEP) in the ALVEOLI cohort. FINDINGS: We analysed data for 1022 patients: 473 in the ARMA cohort and 549 in the ALVEOLI cohort. Independent latent class models indicated that a two-class (ie, two subphenotype) model was the best fit for both cohorts. In both cohorts, we identified a hyperinflammatory subphenotype (phenotype 2) that was characterised by higher plasma concentrations of inflammatory biomarkers, a higher prevalence of vasopressor use, lower serum bicarbonate concentrations, and a higher prevalence of sepsis than phenotype 1. Participants in phenotype 2 had higher mortality and fewer ventilator-free days and organ failure-free days in both cohorts than did those in phenotype 1 (p<0·007 for all). In the ALVEOLI cohort, the effects of ventilation strategy (high PEEP vs low PEEP) on mortality, ventilator-free days and organ failure-free days differed by phenotype (p=0·049 for mortality, p=0·018 for ventilator-free days, p=0·003 for organ-failure-free days). INTERPRETATION: We have identified two subphenotypes within ARDS, one of which is categorised by more severe inflammation, shock, and metabolic acidosis and by worse clinical outcomes. Response to treatment in a randomised trial of PEEP strategies differed on the basis of subphenotype. Identification of ARDS subphenotypes might be useful in selecting patients for future clinical trials. FUNDING: National Institutes of Health.
Authors: Polly E Parsons; Michael A Matthay; Lorraine B Ware; Mark D Eisner Journal: Am J Physiol Lung Cell Mol Physiol Date: 2004-10-29 Impact factor: 5.464
Authors: G R Bernard; A Artigas; K L Brigham; J Carlet; K Falke; L Hudson; M Lamy; J R Legall; A Morris; R Spragg Journal: Am J Respir Crit Care Med Date: 1994-03 Impact factor: 21.405
Authors: Ashish Agrawal; Michael A Matthay; Kirsten N Kangelaris; John Stein; Jeffrey C Chu; Brandon M Imp; Alfredo Cortez; Jason Abbott; Kathleen D Liu; Carolyn S Calfee Journal: Am J Respir Crit Care Med Date: 2013-04-01 Impact factor: 21.405
Authors: V Marco Ranieri; Gordon D Rubenfeld; B Taylor Thompson; Niall D Ferguson; Ellen Caldwell; Eddy Fan; Luigi Camporota; Arthur S Slutsky Journal: JAMA Date: 2012-06-20 Impact factor: 56.272
Authors: Richard D Fremont; Tatsuki Koyama; Carolyn S Calfee; William Wu; Lesly A Dossett; Fred R Bossert; Daphne Mitchell; Nancy Wickersham; Gordon R Bernard; Michael A Matthay; Addison K May; Lorraine B Ware Journal: J Trauma Date: 2010-05
Authors: Maurizio Cereda; Yi Xin; Hooman Hamedani; Giacomo Bellani; Stephen Kadlecek; Justin Clapp; Luca Guerra; Natalie Meeder; Jennia Rajaei; Nicholas J Tustison; James C Gee; Brian P Kavanagh; Rahim R Rizi Journal: Thorax Date: 2017-06-20 Impact factor: 9.139
Authors: Nuala J Meyer; John P Reilly; Rui Feng; Jason D Christie; Stanley L Hazen; Carolyn J Albert; Jacob D Franke; Celine L Hartman; Jane McHowat; David A Ford Journal: JCI Insight Date: 2017-12-07
Authors: José A Lorente; Pablo Cardinal-Fernández; Diego Muñoz; Fernando Frutos-Vivar; Arnaud W Thille; Carlos Jaramillo; Aida Ballén-Barragán; José M Rodríguez; Oscar Peñuelas; Guillermo Ortiz; José Blanco; Bruno Valle Pinheiro; Nicolás Nin; María del Carmen Marin; Andrés Esteban; Taylor B Thompson Journal: Intensive Care Med Date: 2015-09-18 Impact factor: 17.440
Authors: Elizabeth A Middleton; Matthew T Rondina; Hansjorg Schwertz; Guy A Zimmerman Journal: Am J Respir Cell Mol Biol Date: 2018-07 Impact factor: 6.914
Authors: Carolyn S Calfee; Kevin L Delucchi; Pratik Sinha; Michael A Matthay; Jonathan Hackett; Manu Shankar-Hari; Cliona McDowell; John G Laffey; Cecilia M O'Kane; Daniel F McAuley Journal: Lancet Respir Med Date: 2018-08-02 Impact factor: 30.700
Authors: John P Reilly; Nuala J Meyer; Michael Gs Shashaty; Brian J Anderson; Caroline Ittner; Thomas G Dunn; Brian Lim; Caitlin Forker; Michael P Bonk; Ethan Kotloff; Rui Feng; Edward Cantu; Nilam S Mangalmurti; Carolyn S Calfee; Michael A Matthay; Carmen Mikacenic; Keith R Walley; James Russell; David C Christiani; Mark M Wurfel; Paul N Lanken; Muredach P Reilly; Jason D Christie Journal: J Clin Invest Date: 2021-01-04 Impact factor: 14.808
Authors: Edward J Schenck; Clara Oromendia; Lisa K Torres; David A Berlin; Augustine M K Choi; Ilias I Siempos Journal: Chest Date: 2018-10-22 Impact factor: 9.410